Received US Institutional Review Board (IRB) approval for pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) and engaged leading contract research organization (CRO); On track to begin ...

Independent Data Monitoring Committee to Perform Interim Analysis of Phase 3 REGAL Study in January 2025 - - SLS009: Full Topline Phase 2 Data in Acute Myeloid Leukemia and FDA Regulatory Review Expec ...

The cancer fund was founded by and in named in honor of the late Marie Mazziotta, Mark and Bob’s sister, who died in 2006 at ...

LONDON, UK / ACCESSWIRE / January 8, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that it has raised £340,000 through the issue of 100,000 new ordinary shares ('Placing ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

In a significant advancement for cancer research, a team of scientists from Max Planck Institute for Biology Tübingen, ...

Two posters presented at the 2024 American Society of Hematology meeting reported real-world outcomes data for patients ...

Olaparib improved invasive disease-free survival, distant disease-free survival, and overall survival in high-risk ...

Researchers sought to determine if HRQoL measures differ with gilteritinib compared with placebo in patients with AML.

Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic ...

Aug. 21, 2024 — An international team of scientists has uncovered a mechanism by which acute myeloid leukemia (AML) cells sustain their growth. AML cells prevent the synthesis of proteins that ...